Therapeutic agent for hearing loss

New chemical entities can rescue from hearing loss caused by a chemotherapy drug cisplatin

Advantages

  •  It has a potential to treat not only drug-induced hearing loss but also that from other cause
  • Good pharmacokinetics and low toxicity in rodent study are confirmed

Background and Technology

Platinum chemotherapy and aminoglycoside antibiotics damage sensory hair cells in the inner ear, causing sensorineural hearing loss.  Otherwise, hearing disorder is a common problem caused by noise, aging, disease, heredity and idiopathy. Although a lot of people suffer from auditory disorder, there are few therapy and drug that satisfy the QOL of patient.

We synthesized several modulators for a certain ion channel that is reported a relationship to auditory function. It was observed that a synthesized ion channel modulator rescued mouse from hearing deficiency caused by administration of cisplatin

Data

  • Deafness model was induced by administration of cisplatin (CDDP: 12mg/kg i.p.) in mice of which hearing threshold to sounds of each frequency was elevated (Blue bar).
  • The elevation of hearing threshold was suppressed by administration (p.o.) of the compound (10mg/kg/day: Blue vs Orange bar).

Patent

Pending in Japan.

Expectations

Under CDA, we can disclose more information such as the target ion channel,  its compound, and PK & toxicology profile.  In addition, we can also provide the synthesized compound for your feasibility study with
onerous evaluation agreement or MTA.

Product No:WL-03209

 

Medicine

Updated
Published

Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name

Message

Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.

<Notice>

Our support is provided free of charge.
The information submitted on this form is for business development use only.

About Bionauts.jp Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.